The vote as far as I am aware consists of a panel of 10. In...

The vote as far as I am aware consists of a panel of 10. In MSB's instance, the vote was 9 FOR and 1 AGAINST. That was the first time around (I'm guessing the vote was less favourable the second time around).

It sent the price crashing. The second time around I really thought it would get through however as someone else suggested, instead of doing what the FDA asked for, they tried to go their own way and they found out that if you play silly games, you win silly prizes.

I was following this closely at the time because I have MSB shares in my super and was interested in the approval process.

So to answer your question, yes it can take 1 person on the FDA panel to delay your approval, however, had they had jumped through the hoops, they would have been approved the second time around, instead, they are going for a third time AND burning capital in doing so, instead of being able to sell their drug to patients in need.

The moral of the story is:

The FDA asks you to jump.... You jump your little heart out